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Preface 
 
 
Living organisms contain various bioactive macromolecules such as 
proteins and nucleic acids, as well as bioactive small molecules like amino 
acids, vitamins, and hormones. These molecules function cooperatively to 
maintain homeostasis. The rapid development of various metabolomic 
techniques has underscored the importance of investigating small, 
endogenous, bioactive molecules for understanding the homeostasis and 
pathogenesis of higher-level physiological functions. 
In particular, the amounts of bioactive small molecules in maternal 
body are altered significantly during pregnancy. Recent dramatic changes 
in lifestyle have led to an increase in the prevalence of various 
complications of pregnancy. During pregnancy, some of bioactive amines, 
such as monoamines, diamine and peptides, which commonly contain 
primary or secondary amino groups, have been known to be involved in the 
maintenance of blood pressure homeostasis, and variations in their 
concentrations have been observed in various cardiovascular diseases. As 
an example of these bioactive amines, angiotensin II (AngII), a potent 
vasoconstrictor derived from renin-angiotensin system, is a major 
regulative amine of blood pressure, not only under normal conditions but 
also under pregnant state. 
  
Pregnancy-induced hypertension (PIH) is a common complication 
that occurs in approximately 10% of human pregnancies. Pregnant women 
with PIH may display transient blood pressure elevation, proteinuria, 
cardiac hypertrophy, edema, organ dysfunction, intrauterine growth 
retardation (IUGR), and perinatal death in late pregnancy. This syndrome 
places both mother and fetus at high risk; however, its pathogenic 
mechanism is still unclear despite numerous clinical studies. Further 
investigation has been hindered by ethical issues involved in research on 
PIH patients and technical limits derived from the lack of an appropriate 
animal model for this disease. 
 It has recently been theorized that AngII was one of causes in the 
pathogenesis of PIH. Our laboratory previously developed a transgenic 
mouse model in which pregnancy-associated hypertension (PAH) 
developed due to the overproduction of AngII in the maternal circulation 
during late pregnancy. PAH mice showed a transient elevation of blood 
pressure, proteinuria, cardiac hypertrophy, IUGR, and perinatal death in 
late gestation. These gestational disorders are caused by excessive AngII – 
type I angiotensin II receptor (AT1R) signaling. However, the mechanisms 
involved in the downstream of the AngII–AT1R system are unknown. 
 I hypothesized that the pathogenesis of PIH would be affected by 
disruption of the quantitative balance of bioactive amines during pregnancy. 
I used PAH mice as a tool for studies on human PIH, and tried to explore 
  
and identify the bioactive amines involved in the pathogenesis of PAH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results 
 
 
HPLC analyses of plasma through detections of amino group containing 
substances from both WT and PAH mice at day 19 of gestation revealed 
that the amount of a specific peak at 15.5 min from PAH mice was 
relatively higher than that from WT mice. Following this screening, I 
performed mass analysis with MALDI-QIT-TOF/MS and structural 
analysis with 1H NMR. The isolated molecule had a molecular mass of 
111.25 and contained an imidazole ring in its structure. I searched for a 
candidate substance using the Spectral Database for Organic Compounds 
(SDBS), and revealed that histamine was the primary candidate amine. The 
retention time of commercial histamine standard was identical to that of the 
identified amine on the HPLC chromatogram. Furthermore, MS and 
MS/MS spectra of histamine corresponded to that of the target amine. 
These results suggest that the characterized substance as an elevated amine 
in PAH mice was histamine. After I established the measuring method for 
trace amounts of histamine in cultured cells by using ultra-high 
performance liquid chromatography (UPLC), I applied it for absolute 
quantitative analysis of histamine in mice plasma, and revealed that plasma 
histamine levels of PAH mice were 1.7-fold significantly higher than that 
of WT mice. 
  
Discussion 
 
 
Pregnancy-induced hypertension (PIH) is a high-risk disease for both 
mother and baby; however, the underlying pathogenic mechanisms of PIH 
remain to be solved despite many intensive clinical investigations. 
Identifying these mechanisms will contribute greatly to the development of 
effective therapies. 
I focused on small molecules essential for progression of gestation, 
and explored the bioactive amines involved in the pathogenesis of PAH 
using HPLC, MALDI-QIT-TOF/MS, and 1H NMR. The results of these 
analyses showed that plasma histamine levels in PAH mice were higher 
than those in WT mice at day 19 of gestation. 
Histamine is well known to be involved in a variety of 
physiological responses, such as allergy, inflammation, gastric acid 
secretion, and neurotransmission. Histamine is synthesized by histidine 
decarboxylase (HDC) with L-histidine as a specific substrate. On the other 
hand, it is metabolized in two ways: one is via oxidative deamination by 
diamine oxidase (DAO), and the other is via imidazole ring-methylation by 
histamine-N-methyltransferase (HNMT), an enzyme that converts 
histamine to 3-methyl histamine only in the cytoplasm. It has been reported 
that histamine levels are elevated during the third trimester in pregnant 
  
women with PIH, and the clinical manifestations of PIH resemble those of 
hyperhistaminemia. It has also been reported that histamine may inhibit 
apoptotic activity in trophoblast cell cultures via the H1 receptor. Although 
the relationship between histamine and PIH was investigated in the 1950s, 
the functions of histamine in PIH have not been fully examined. Because 
experiments in PIH patients conflict with ethical guidelines, we could not 
conduct further investigations. 
In the present study, I was not able to clarify whether or not 
histamine plays a causal role in PAH. By using PAH mice, we can perform 
future studies on human PIH without ethical limitations. Future analyses of 
PAH mice will help to elucidate the molecular mechanisms underlying 
human PIH and lead to the development of new therapies. 
